

## Special Issue

# Breast Cancer Bone Metastasis

### Message from the Guest Editors

Bone metastases remain a significant challenge in medicine. They are common in advanced breast cancer, leading to considerable morbidity and mortality, and serve as a well-studied example of the mechanisms underlying invasion and metastasis. Notably, breast cancer stands out as the only cancer for which bone metastasis prevention has been achieved using bone-targeted agents. This distinction underscores the progress made in breast cancer research and highlights the potential for similar advances in other cancers. Patients with bone metastases from breast cancer, particularly those with luminal disease, can live for years with appropriate treatment. This usually involves anticancer agents in association with bone-targeted agents and a comprehensive multidisciplinary approach, including radiotherapy and surgery. The combined efforts of different specialties are essential to improving patient outcomes and their quality of life. In this issue, we invite you to explore key clinical features and join us in addressing new questions surrounding bone metastases in breast cancer. Your contributions will help advance understanding and promote innovative solutions in this critical area.

---

### Guest Editors

Prof. Dr. Allan Lipton

Hematology-Oncology, Department of Medicine, Penn State University School of Medicine, Hershey, PA 17033, USA

Prof. Dr. Louis Costa

1. Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Avenida Professor Egas Moniz MB, 1649-028 Lisboa, Portugal

2. Institute of Molecular Medicine João Lobo Antunes, Faculty of Medicine, University of Lisbon, Avenida Professor Egas Moniz MB, 1649-028 Lisboa, Portugal

---

### Deadline for manuscript submissions

27 November 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/278215](https://mdpi.com/si/278215)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)